TRML TOURMALINE BIO INC

Tourmaline Bio to Present at Upcoming Investor Conferences

Tourmaline Bio to Present at Upcoming Investor Conferences

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences:

Truist Securities BioPharma Symposium, New York

Panel: Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle Illnesses

Thursday, November 7, 2024 at 2:35 pm ET

Guggenheim Securities Healthcare Innovation Conference, Boston

Fireside Chat

Tuesday, November 12, 2024 at 1:30 pm ET

Live webcasts and replays, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at .

For more information about Tourmaline Bio and pacibekitug, please visit or follow us on or .

About Tourmaline Bio

Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).

Media Contact

Scient PR

Sarah Mishek

  

Investor Contact

Meru Advisors

Lee M. Stern



EN
31/10/2024

Underlying

TRMLTOURMALINE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on TOURMALINE BIO INC

Laura Chico
  • Laura Chico
TRML TOURMALINE BIO INC
10/31/25 October 31, 2025 1 EN
Wedbush Research
  • Wedbush Research
LEN LENNAR CORPORATION CLASS A
AAPL APPLE INC.
IDYA IDEAYA BIOSCIENCES
TRML TOURMALINE BIO INC
CBIO CRESCENT BIOPHARMA INC.
09/09/25 September 9, 2025 1 EN
Laura Chico
  • Laura Chico
TRML TOURMALINE BIO INC
09/09/25 September 9, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG – Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential, for the treatment of cardiovascular diseases – – Transaction is expected to be completed in the fourth quarter of 2025, subject to customary closing conditions – NEW YORK, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”)...

September 9, 2025 1 EN
 PRESS RELEASE
Free
TRML TOURMALINE BIO ...

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Tria...

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress – Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary pharmacodynamic biomarkers of IL-6 pathway activity including lipoprotein(a), fibrinogen, and serum amyloid A – NEW YORK, Aug. 31, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage c...

August 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch